NCT Number: NCT07186439
Pulmonary Hypertension Screening in Scleroderma
Screening for pulmonary hypertension in scleroderma patients
Trial opening soon.
Get NotifiedKey information
Conditions
Age range
18 year–80 year
Sex eligibility
All sexes
Study type
Observational
About this study
Scleroderma is a heterogenous connective tissue disorder characterized by fibrosis of the skin, with or without internal organ involvement. The aetiology of scleroderma may involve both environmental and genetic factors. Abnormalities involving the immune system, vascular tissue and extracellular matrix have been demonstrated.
One of the major cause of mortality in patients with scleroderma is pulmonary arterial hypertension (PAH). International recommendations advise annual screening for the early detection of PAH in asymptomatic patients with scleroderma.
scleroderma is group 1 in clinical classification of pulmonary hypertension Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) >20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR >2 Wood Units (WU)), isolated post-capillary PH (PAWP >15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP >15 mmHg, PVR >2 WU) Scleroderma has an annual prevalence of one to five cases for every 1000 individuals and nearly 15 percent of all cases develop PAH. A diagnosis of PAH in Scleroderma is virtually a death sentence, with studies reporting a mortality rate of 50 per cent in the 3 years of diagnosis. Therefore, developing and implementing screening and diagnosis protocol is important in the fight against this disease. echocardiography as the leading screening tool for scleroderma -PAH. In particular, systolic pulmonary arterial pressure (sPAP) and tricuspid regurgitation velocity (TRV). Echocardiography is non invasive tool for eary screening in pulmonary hypertension according ESC-ERS guideline If the peak tricuspid regurgitation velocity (TRV) is ≤ 2.8 m/s or not measurable, and there are no other echocardiographic signs of pulmonary hypertension, the probability is low.
If the TRV is ≤ 2.8 m/s or not measurable, but other echocardiographic signs of pulmonary hypertension are present, the probability is intermediate low
If the TRV is between 2.9 and 3.4 m/s and no other signs are present, the probability is intermediate high
If the TRV is between 2.9 and 3.4 m/s and other signs are present, the probability is high.
PH probability LOW → other causes . PH probability ntermediate low → follow up Echocardiography PH probability INTERMEDIATE high or HIGH → right heart catheterization Additional echocardiographic signs suggestive of pulmonary hypertension
A: The ventricles
RV/LV basal diameter area ratio ≥1.0
Flattening of the interventricular septum (LVEI >1.1 in systole and/or diastole)
TAPSE / sPAP ratio <0.55 mm/mmHg
B: Pulmonary artery
RVOT AT <105 ms and/or mid-systolic notching
Early diastolic pulmonary regurgitation velocity >2.2 m/s
PA diameter >25 mm
RPA diameter >25 mm
C: Inferior vena cava and RA
IVC diameter >21 mm with decreased inspiratory collapse (<50% with a sniff or <20% with quiet inspiration)
RA area (end-systole) >18 cm²
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- . Inclusion criteria: aga ≥18 years confirmed diagnosis of scleroderma
Exclusion criteria
- aga <18 years
- patients refused to participate
Treatment and study plan
Primary outcomes
-
Screening for pulmonary hypertension in scleroderma patients
Time frame: baseline
detection rate of pulmonary hypertension in scleroderma by Echocardiography
Study contacts
Contact information is provided by the study sponsor or research team.
Esraa Sayed Abdalzeaz, Resident doctor
CONTACT
Gamal Mohmed Rabea, Professor
CONTACT
Sponsors and collaborators
Lead sponsor
Assiut University
Other
Registry information
Important dates
- Study start
- 2025
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Sep 22, 2025
- Registry last updated
- Sep 24, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.